Enterohepatic recirculation of bioactive ginger phytochemicals is associated with enhanced tumor growth-inhibitory activity of ginger extract

Carcinogenesis

Volumn 35, Issue 6, 2014, Pages 1320-1329

  Gundala, Sushma R ^a   Mukkavilli, Rao ^b   Yang, Chunhua ^a   Yadav, Pooja ^c   Tandon, Vibha ^c   Vangala, Subrahmanyam ^b   Prakash, Satya ^d   Aneja, Ritu ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Advinus Therapeutics Private Limited Bangalore   (India)

^c UNIVERSITY OF DELHI   (India)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

(10) GINGEROL; (6) GINGEROL; (8) GINGEROL; 6 SHOGAOL; ANTINEOPLASTIC AGENT; GINGER EXTRACT; GINGEROL; UNCLASSIFIED DRUG; CATECHOL DERIVATIVE; FATTY ALCOHOL; PHENOL DERIVATIVE; PLANT EXTRACT; PLANT MEDICINAL PRODUCT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG PROTEIN BINDING; ELIMINATION RATE CONSTANT; ENTEROHEPATIC CIRCULATION; GINGER; HEPATIC AVAILABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PHYTOCHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; VOLUME OF DISTRIBUTION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; INTRAVENOUS ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR VOLUME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATECHOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENTEROHEPATIC CIRCULATION; FATTY ALCOHOLS; GINGER; HUMANS; MALE; MICE; PHENOLS; PHYTOCHEMICALS; PLANT EXTRACTS; PROSTATIC NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902310829     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu011     Document Type: Article

References (47)

1. HemaIswarya, S. et al. (2006) Potential synergism of natural products in the treatment of cancer. Phytother. Res., 20, 239-249.
2. Jacobs, D.R. Jr et al. (2009) Food synergy: an operational concept for understanding nutrition. Am. J. Clin. Nutr., 89, 1543S-1548S.
3. Liu, R.H. (2003) Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am. J. Clin. Nutr., 78, 517S-520S.
4. Liu, R.H. (2004) Potential synergy of phytochemicals in cancer prevention: mechanism of action. J. Nutr., 134, 3479S-3485S.
5. Wagner, H. (2011) Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia, 82, 34-37.
6. Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med., 330, 1029-1035.
7. Greenberg, E.R. et al. (1994) A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N. Engl. J. Med., 331, 141-147.
8. Tsao, A.S. et al. (2004) Chemoprevention of cancer. CA. Cancer J. Clin., 54, 150-180.
9. Manach, C. et al. (2004) Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr., 79, 727-747.
10. Manach, C. et al. (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 81, 230S-242S.
11. Williamson, G. et al. (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am. J. Clin. Nutr., 81, 243S-255S.
12. Silberberg, M. et al. (2006) The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur. J. Nutr., 45, 88-96.
13. Calani, L. et al. (2012) Colonic metabolism of polyphenols from coffee, green tea, and hazelnut skins. J. Clin. Gastroenterol., 46, S95-S99.
14. Govindarajan, V.S. (1982) Ginger-chemistry, technology, and quality evaluation: part 1. Crit. Rev. Food Sci. Nutr., 17, 1-96.
15. Govindarajan, V.S. (1982) Ginger-chemistry, technology, and quality evaluation: part 2. Crit. Rev. Food Sci. Nutr., 17, 189-258.
16. Tao, Y. et al. (2009) Identification and quantification of gingerols and related compounds in ginger dietary supplements using high-performance liquid chromatography-tandem mass spectrometry. J. Agric. Food Chem., 57, 10014-10021.
17. Vasala, P.A. (2004) Ginger. In Peter, K.V. (ed.), Handbook of Herbs and Spices. Vol. I. Woodhead, Cambridge, England.vol. I.
18. Yoshikawa, M. et al. (1993) [Qualitative and quantitative analysis of bioactive principles in Zingiberis Rhizoma by means of high performance liquid chromatography and gas liquid chromatography. On the evaluation of Zingiberis Rhizoma and chemical change of constituents during Zingiberis Rhizoma processing]. Yakugaku Zasshi, 113, 307-315.
19. Jeong, C.H. et al. (2009) [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res., 69, 5584-5591.
20. Kim, S.O. et al. (2005) [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol esterstimulated mouse skin. Oncogene, 24, 2558-2567.
21. Lee, H.S. et al. (2008) [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J. Nutr. Biochem., 19, 313-319.
22. Kundu, J.K. et al. (2009) Ginger-derived phenolic substances with cancer preventive and therapeutic potential. Forum Nutr., 61, 182-192.
23. Lumb, A.B. (1994) Effect of dried ginger on human platelet function. Thromb. Haemost., 71, 110-111.
24. Park, K.K. et al. (1998) Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett., 129, 139-144.
25. Park, Y.J. et al. (2006) [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei Med. J., 47, 688-697.
26. Shukla, Y. et al. (2007) Cancer preventive properties of ginger: a brief review. Food Chem. Toxicol., 45, 683-690.
27. Wang, C.C. et al. (2003) Effects of 6-gingerol, an antioxidant from ginger, on inducing apoptosis in human leukemic HL-60 cells. In Vivo, 17, 641-645.
28. Zick, S.M. et al. (2008) Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev., 17, 1930-1936.
29. Zick, S.M. et al. (2010) Quantitation of 6-, 8-and 10-gingerols and 6-shogaol in human plasma by high-performance liquid chromatography with electrochemical detection. Int. J. Biomed. Sci., 6, 233-240.
30. Chen, C.Y. et al. (2009) Effect of [10]-gingerol on [ca2+]i and cell death in human colorectal cancer cells. Molecules, 14, 959-969.
31. Dugasani, S. et al. (2010) Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J. Ethnopharmacol., 127, 515-520.
32. Karna, P. et al. (2012) Benefits of whole ginger extract in prostate cancer. Br. J. Nutr., 107, 473-484.
33. Brahmbhatt, M. et al. (2013) Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. Nutr. Cancer, 65, 263-272.
34. Reagan-Shaw, S. et al. (2008) Dose translation from animal to human studies revisited. FASEB J., 22, 659-661.
35. Gad, S.C. (ed.) (2007) The mouse. In Animal Models in Toxicology. CRC Press, Taylor & Francis Group, Boca Raton, FL, pp. 19-146.
36. Roberts, M.S. et al. (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet., 41, 751-790.
37. Baliga, M.S. et al. (2011) Update on the chemopreventive effects of ginger and its phytochemicals. Crit. Rev. Food Sci. Nutr., 51, 499-523.
38. Jacobs, D.R. Jr et al. (2007) Food, not nutrients, is the fundamental unit in nutrition. Nutr. Rev., 65, 439-450.
39. Ulbricht, C.E. et al. (2010) Phytochemicals in the oncology setting. Curr. Treat. Options Oncol., 11, 95-106.
40. Wells, P.G. et al. (2004) Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos., 32, 281-290.
41. Jana, S. et al. (2009) Role of phase II drug metabolizing enzymes in cancer chemoprevention. Curr. Drug Metab., 10, 595-616.
42. Bravo, L. (1998) Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev., 56, 317-333.
43. Olson, J.A. et al. (1992) Enhancement of biological activity by conjugation reactions. J. Nutr., 122, 615-624.
44. McCarver, D.G. et al. (2002) The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther., 300, 361-366.
45. Gregory, P.A. et al. (2004) Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol. Appl. Pharmacol., 199, 354-363.
46. Ritter, J.K. (2000) Roles of glucuronidation and UDPglucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact., 129, 171-193.
47. Liu, Z. et al. (2007) Natural polyphenol disposition via coupled metabolic pathways. Expert Opin. Drug Metab. Toxicol., 3, 389-406.